iTeos Therapeutics

iTeos Therapeutics is targeting the tumor microenvironment to enhance the effectiveness of T-cells at eradicating cancer. iTeos has a broad pipeline focused on multiple complementary mechanisms of action including small molecules targeting A2A as well as antibodies directed to TIGIT.